Chembio Diagnostics develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Co.'s product portfolio is based upon its proprietary DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the diagnostic test market, which includes infectious diseases, cardiac markers and drugs of abuse. The DPP technology platform can provide sensitivity and specificity, multiplexing capabilities and, with the DPP Micro Reader, quantitative results. The CEMI stock yearly return is shown above.
The yearly return on the CEMI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CEMI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|